Faculty of Pharma Sciences, Teikyo University Lab page | Japanese
Laboratory of Pharmaceutics
Publication List (Journals)
1.
 Predicting muscarinic receptor occupancy in human bladder mucosa from urinary concentrations of antimuscarinic agents for overactive bladder; Shiho M, Akashita G, Nakatani E, Tanaka S, Yamada S, Okura T; Drug Metabolism and Pharmacokinetics, 56, 100998-100998 (2024)
2.
 Evaluation of dementia risk in patients taking medication for overactive bladder using medication history in Japan.; Tanaka S, Miyata S, Yamato J, Kumagai S, Kogawa M, Yamori T, Irie M, Nakatani E, Okura T.; Translational and Regulatory Sciences, 6(1), 10-14(2024)
3.
 Development of an on-site therapeutic drug monitoring method using a portable spectrometer. ;Todoroki K, Fukudo N, Kudoh Y, Mizuno H, Jun Zhe Min, Tanaka S, Uchida S, Namiki N, Toyo'oka T.; Analytical sciences : the international journal of the Japan Society for Analytical Chemistry; 40(5), 863-869(2024)
4.
 Deficiency of long-chain acyl-CoA synthetase 4 leads to lipopolysaccharide-induced mortality in a mouse model of septic shock. ; Kuwata H, Nakatani E, Tomitsuka Y, Ochiai T, Sasaki Y, Yoda E, Hara S.; FASEB J., 37(12), e23330 (2023)
5.
 Improved Palatability of Gummy Drugs of Epinastine Hydrochloride Using Organoleptic Taste-Masking Methods.;Tanaka S, Kawamoto S, Kashiwagura Y, Hakamata A, Odagiri K, Okura T, Inui N, Watanabe H, Namiki N, Uchida S.; BPB Reports., 6(6) 184-188 (2023)
6.
 Palatability of Aripiprazole Gummies Prepared from Commercially Available Products: Pharmaceutical Formulation for Improving Patient Adherence.; Kawamoto S, Tanaka S, Miura M, Kashiwagura Y, Kamiya C, Hakamata A, Odagiri K, Inui N, Watanabe H, Namiki N.; Chemical and Pharmaceutical Bulletin., 71(6) 441-446(2023)
7.
 Tablet characteristics and pharmacokinetics of orally disintegrating tablets containing coenzyme Q10 granules prepared by different methods.; Kashiwagura Y, Takusagawa S, Ikematsu Y, Tanaka S, Namiki N, Uchida S.; Acta pharmaceutica., 73(1) 107-119 (2023)
8.
 Efficacy and safety of propranolol cream in infantile hemangioma: A prospective pilot study.; Nagata E, Kashiwagura Y, Okada E, Tanaka S, Sano S, Nishida M, Hayano S, Iwashima S, Hakamata A, Odagiri K.; Journal of pharmacological sciences., 149(2) 60-65(2022)
9.
 Increased plasma drug concentration and decreased additional insulin secretion following oral administration of glimepiride in Spontaneously Diabetic Torii rats.; Miura M, Tanaka S, Ikeda M, Kawakami J, Watanabe H, Namiki N, Uchida S.; Pharmazie., 77(1) 6-8 (2022)
10.
 Topical Formulations of Propranolol for Infantile Hemangiomas: Characteristics of Formulations and Three Cases of Infants Administered Topical Propranolol Cream.; Kashiwagura Y, Hakamata A, Shirai M, Endoh A, Tanaka S, Inui N, Watanabe H, Namiki N, Uchida S.; Chemical & pharmaceutical bulletin., 70(4) 277-282(2022)
11.
 Naltrexone Transport by a Proton-Coupled Organic Cation Antiporter in hCMEC/D3 Cells, an in Vitro Human Blood-Brain Barrier Model. ; Kitamura A, Higuchi K, Kurosawa T, Okura T, Kubo Y, Deguchi Y.; Biological & pharmaceutical bulletin., 45(10) 1585-1589 (2022)
12.
 Extracellular Vesicles Derived from 3T3-L1 Adipocytes Enhance Procoagulant Activity.; Nakatani E, Naito Y, Ishibashi K, Ohkura N, Atsumi G.; Biological & pharmaceutical bulletin., 45(2) 178-183 (2022)
13.
 Muscarinic receptor binding activity in rat tissues by vibegron and prediction of its receptor occupancy levels in the human bladder.; Yamada S, Chimoto J, Shiho M, Okura T, Morikawa K, Kagota S, Shinozuka K.; International journal of urology., 28(12) 1298-1303 (2021)
14.
 Possible Involvement of Muscarinic Receptor Blockade in Mirabegron Therapy for Patients with Overactive Bladder.; Yamada S, Chimoto J, Shiho M, Okura T, Morikawa K, Wakuda H, Shinozuka K.; The Journal of pharmacology and experimental therapeutics., 377(2) 201-206 (2021)
15.
 An educational intervention improved knowledge of dietary supplements in college students.; Chiba T, Kobayashi E, Okura T, Sekimoto M, Mizuno H, Saito M, Umegaki K.; BMC Public Health., 20(1) 633-633 (2020)
16.
 Long-chain acyl-CoA synthetase 4 participates in the formation of highly unsaturated fatty acid-containing phospholipids in murine macrophages.; Kuwata H, Nakatani E, Matsubayashi S, Ishikawa F, Shibanuma M, Sasaki Y, Yoda E, Nakatani Y, Hara S.; Biochim Biophys Acta Mol Cell Biol Lipids., 1864(11) 1606-1618 (2019)
17.
 Effects of Anticholinergic Drugs Used for the Therapy of Overactive Bladder on P-Glycoprotein Activity.; Wakuda H, Okura T, Maruyama-Fumoto K, Kagota S, Ito Y, Miyauchi-Wakuda S, Otani N, Uemura N, Yamada S, Shinozuka K.; Biological & pharmaceutical bulletin., 42(12) 1996-2001 (2019)
18.
 Prostaglandin Transporter OATP2A1/SLCO2A1 Is Essential for Body Temperature Regulation during Fever.; Nakamura Y, Nakanishi T, Shimada H, Shimizu J, Aotani R, Maruyama S, Higuchi K, Okura T, Deguchi Y, Tamai I.; The Journal of neuroscience : the official journal of the Society for Neuroscience., 38(24) 5584-5595 (2018)
19.
 Involvement of proton-coupled organic cation antiporter in varenicline transport at blood-brain barrier of rats and in human brain capillary endothelial cells.; Kurosawa T, Higuchi K, Okura T, Kobayashi K, Kusuhara H, Deguchi Y; J. Pharm. Sci., in press (2017)
20.
 Activation of PPARγ at an early stage of differentiation enhances adipocyte differentiation of MEFs derived from Type II diabetic TSOD mice and alters lipid droplet morphology.; Ishibashi K, Takeda Y, Nakatani E, Sugawara K, Imai R, Sekiguchi M, Takahama R, Ohkura N, Atsumi G; Biol. Pharm. Bull. in press (2017)
21.
 Histamine elimination from the cerebrospinal fluid across the blood-cerebrospinal fluid barrier: involvement of plasma membrane monoamine transporter (PMAT/SLC29A4).; Usui T, Nakazawa A, Okura T, Deguchi Y, Akanuma SI, Kubo Y, Hosoya KI; J Neurochem. 139(3), 408-418 (2016)
22.
 Cocktail-dosing microdialysis study to simultaneously assess delivery of multiple organic-cationic drugs to the brain.; Kitamura A, Okura T, Higuchi K, Deguchi Y; J. Pharm. Sci. 105(2), 935-940 (2016)
23.
 The blood-brain barrier transport mechanism controlling analgesic effects of opioid drugs in CNS; Okura T, Higuchi K, Deguchi Y.; Yakugaku Zasshi. 135(5):697-702 (2015)
24.
 Memantine transport by a proton-coupled organic cation antiporter in hCMEC/D3 cells, an in vitro human blood-brain barrier model.; Higuchi K, Kitamura A, Okura T, Deguchi Y; Drug Metab Pharmacokinet., 30(2), 182-187 (2015)
25.
 Transport characteristics of tramadol in the blood-brain barrier.; Kitamura A, Higuchi K, Okura T, Deguchi Y; J. Pharm. Sci., 103(10), 3335-3341 (2014)
26.
 Proton-coupled organic cation antiporter-mediated uptake of apomorphine enantiomers in human brain capillary endothelial cell line hCMEC/D3.; Okura T, Higuchi K, Kitamura A, Deguchi Y; Biol Pharm Bull., 37 (2), 286-291 (2014)
27.
 Functional expression of organic cation/carnitine transporter 2 (OCTN2/SLC22A5) in human brain capillary endothelial cell line hCMEC/D3, a human blood-brain barrier model.; Okura T, Kato S, Deguchi Y; Drug Metab Pharmacokinet., 29 (1), 69-74 (2014)
28.
 Endothelin-1 receptors in rat tissues: characterization by bosentan, ambrisentan and CI-1020.; Yokoyama Y, Osano A, Hayashi H, Itoh K, Okura T, Deguchi Y, Ito Y, Yamada S; Biol. Pharm. Bull., 37 (3), 461-465 (2014)
29.
 Bladder endothelin-1 receptor binding of bosentan and ambrisentan.; Osano A, Yokoyama Y, Hayashi H, Itoh K, Okura T, Deguchi Y, Ito Y, Yamada S; J Pharmacol Sci., 124(1), 86-91 (2014)
30.
 Muscarinic receptor binding of the novel radioligand, [(3)H]imidafenacin in the human bladder and parotid gland.; Yoshida A, Kuraoka S, Ito Y, Okura T, Deguchi Y, Otsuka A, Ozono S, Takeda M, Masuyama K, Araki I, Yamada S; J. Pharmcol. Sci., 124 (1), 40-46 (2014)
31.
 Muscarinic receptor binding of the novel radioligand, [3h]imidafenacin in the human bladder and parotid gland.; Yoshida A, Kuraoka S, Ito Y, Okura T, Deguchi Y, Otsuka A, Ozono S, Takeda M, Masuyama K, Araki I, Yamada S; J Pharmacol Sci. 124(1):40-46 (2014)
32.
 Suppression of murine collagen-induced arthritis by vaccination of synovial vascular endothelial cells; Sawaguchi, Y., Hirata, K., Suzuki, R., Utoguchi, N., Maruyama, K.; Life Sci., 92(23), 1125-1130 (2013)
33.
 Functional expression of a proton-coupled organic cation (H+/OC) antiporter in human brain capillary endothelial cell line hCMEC/D3, a human blood-brain barrier model.; Shimomura K, Okura T, Kato S, Couraud PO, Schermann JM, Terasaki T, Deguchi Y; Fluid Barrier CNS, 10:8, (2013).
34.
 Suppression of murine collagen-induced arthritis by vaccination of synovial vascular endothelial cells.; Sawaguchi Y, Hirata K, Suzuki R, Utoguchi N, Maruyama K; Life Sci.; 92(23), 1125-1130 (2013)
35.
 Prophylactic immunization with Bubble liposomes and ultrasound-treated dendritic cells provided a four-fold decrease in the frequency of melanoma lung metastasis.; Oda Y, Suzuki R, Otake S, Nishiie N, Hirata K, Koshima R, Nomura T, Utoguchi N, Kudo N, Tachibana K, Maruyama K.; J Control Release. 160(2):362-366 (2012)
36.
 Associations between plasma PAI-1 concentrations and its expressions in various organs in obese model mice.; Ohkura N, Shirakura M, Nakatani E, Oishi K, Atsumi G; Thrombosis research 130: e301-4 (2012)
37.
 Diphenhydramine active uptake at the blood-brain barrier and its interaction with oxycodone in vitro and in vivo.; Muhammad Waqas Sadiq, Annika Borgs, Takashi Okura, Keita Shimomura, Sayaka Kato, Yoshiharu Deguchi, Britt Jansson1, Sven Bjorkman, Tetsuya Terasaki, Margareta Hammarlund-Udenaes; J. Pharm. Sci., 100 (9), 3912 - 3923 (2011)
38.
 Functional characterization of rat plasma membrane monoamine transporter in the blood-brain and blood-cerebrospinal fluid barriers.; Okura T, Kato S, Takano Y, Sato T, Yamashita A, Morimoto R, Ohtsuki S, Terasaki T, Deguchi Y; J. Pharm. Sci. 100 (9), 3924 - 3938 (2011)
39.
 Drug-drug interaction between oxycodone and adjuvant analgesics in blood-brain barrier transport and antinociceptive effect.; Nakazawa Y, Okura T, Shimomura K, Terasaki T, Deguchi Y; J. Pharm. Sci., 99(1), 467-474 (2010).
40.
 Effects of dietary ingredients on function and expression of P-glycoprotein in human intestinal epithelial cells.; Okura T, Ibe M, Umegaki K, Shinozuka K, Yamada S; Biol Pharm Bull. 33(2):255-259 (2010)
41.
 Effects of repeated morphine treatment on the antinociceptive effects, intestinal absorption, and efflux from intestinal epithelial cells of morphine.; Okura T, Ozawa T, Ibe M, Taki Y, Kimura M, Kagawa Y, Kato Y, Yamada S; Biol Pharm Bull. 32(9):1571-1575 (2009)
42.
 Effects of quinidine on antinociception and pharmacokinetics of morphine in rats.; Okura T, Morita Y, Ito Y, Kagawa Y, Yamada S; J Pharm Pharmacol. 61(5), 593-597 (2009)
43.
 Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone.; Okura T, Hattori A, Takano Y, Sato T, Hammarlund-Udenaes M, Terasaki T, Deguchi Y; Drug Metab Dispos.; 36(10), 2005-2013 (2008)
44.
 Enhancement by grapefruit juice of morphine antinociception.; Okura T, Ozawa T, Ito Y, Kimura M, Kagawa Y, Yamada S; Biol Pharm Bull.; 31(12), 2338-2341 (2008)
45.
 Blood-brain barrier transport of pramipexole, a dopamine D2 agonist.; Okura T, Ito R, Ishiguro N, Tamai I, Deguchi Y; Life Sci.; 80(17), 1564-1571 (2007)
46.
 Prediction of alpha1-adrenoceptor occupancy in the human prostate from plasma concentrations of silodosin, tamsulosin and terazosin to treat urinary obstruction in benign prostatic hyperplasia.; Yamada S, Kato Y, Okura T, Kagawa Y, Kawabe K; Biol Pharm Bull.; 30(7), 1237-1241 (2007)
47.
 Different effects of morphine and morphine-6beta-glucuronide on formalin-evoked spinal glutamate release in conscious and freely moving rats.; Okura T, Komiyama N, Morita Y, Kimura M, Yamada S; Neurosci Lett.; 415(2), 169-173 (2007)
48.
 Comparative measurement of spinal CSF microdialysate concentrations and concomitant antinociception of morphine and morphine-6beta-glucuronide in rats.; Okura T, Komiyama N, Morita Y, Kimura M, Deguchi Y, Yamada S; Life Sci.; 80(14), 1319-1326 (2007)
Publication List (Books and others)